Clinical Trials | December 03, 2025
Merck unveils first human data for Alzheimer’s candidates
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Subscribe To Our Newsletter & Stay Updated
